Establishment and characterization of a highly tumorigenic African American prostate cancer cell line, E006AA-hT

International Journal of Biological Sciences

Volumn 10, Issue 8, 2014, Pages 834-845

  Koochekpour, Shahriar ^a   Willard, Stacey S ^a   Shourideh, Mojgan ^a   Ali, Shafat ^a   Liu, Chunhong ^a   Azabdaftari, Gissou ^a   Saleem, Mohammad ^b   Attwood, Kristopher ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

African American; Androgen receptor; E006AA; Prostate cancer; Tumorigenic

Indexed keywords

ANDROGEN RECEPTOR;

AFRICAN AMERICAN; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

AFRICAN AMERICANS; CELL LINE, TUMOR; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84906772865     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.9406     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, et al. D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
3. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin 2012; 62: 220-241.
4. DeSantis C, Naishadham D, Jemal A. Cancer statistics for African Americans. CA Cancer J Clin 2013; 63: 151-66.
5. Karami S, Young HA, Henson DE. Earlier age at diagnosis: another dimension in cancer disparity? Cancer Detect Prev 1997; 31: 29-34.
6. Bunker CH. Prostate cancer risk is three-fold higher among men, aged 50-64, of African descent compared with men of Asian-Indian descent in Trinidad and Tobago. Ethn. Dis 2002; 12(S3): 30-33.
7. Bouchardy C, Mirra AP, Khlat M, et al. Ethnicity and cancer risk in Sao Paulo, Brazil. Cancer Epidemiol. Biomarkers Prev 1991; 1: 21-27.
8. Odedina FT, Akinremi TO, Chinegwundoh F, et al. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer 2009; 4(suppl. 1): S2.
9. Ben Shlomo Y, Evans S, Ibrahim F, et al. The risk of prostate cancer amongst Black Men in the United Kingdom: the PROCESS cohort study. Eur Urol 2007; 53: 99-105.
10. Bunker CH, Patrick AL, Konety BR, et al. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol. Biomarkers Prev 2002; 11: 726-729.
11. Osegbe DN. Prostate cancer in Nigerians: facts and nonfacts. J Urol 1997; 157: 1340-1343.
12. Gueye SM, Zeigler-Johnson CM, Friebel T, et al. Clinical characteristics of prostate cancer in African Americans, American whites, and Senegalese men. Urology 2003; 61: 987-992.
13. Angwafo FF 3rd, Zaher A, Befidi-Mengue R, et al. National health survey team for the national epidemiology board of Cameroon. Angwafo FF, III. High-grade intra-epithelial neoplasia and prostate cancer in Dibombari, Cameroon. Prostate Cancer Prostatic Dis 2003; 6: 34-38.
14. Wasike RW, Magoha GA. Descriptive case series of patients presenting with cancer of the prostate and their management at Kenyatta National Hospital, Nairobi. East Afr Med J 2007; 84: S31-S35.
15. Hoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001; 93: 388-395.
16. Evans S, Metcalfe C, Patel B, et al. Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study. Br J Cancer 2010; 102: 249-354.
17. Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control 2009; 20: 417-435.
18. Chu KC, Miller BA, Springfield SA. Measures of racial/ethnic health disparities in cancer mortality rates and the influence of socioeconomic status. J Natl Med Assoc 2007; 99: 1092-1100.
19. Spencer BA, Miller DC, Litwin MS, et al. Variations in quality of care for men with early-stage prostate cancer. J Clin Oncol 2008; 26: 3735-3742.
20. Drake BF, Lathan CS, Okechukwu CA, et al. Racial differences in prostate cancer screening by family history. Ann Epidemiol 2008; 18: 579-583.
21. Gross CP, Smith BD, Wolf E, et al. Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer 2008; 112: 900-908.
22. Freeman VL, Leszczak J, Cooper RS. Race and the histologic grade of prostate cancer. Prostate 1997; 30: 79-84.
23. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines--part 1 and 2. J Urol 2005; 173: 342-372. Review.
24. Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part I. Cell markers and immortalized nontumorigenic cell lines. Prostate 1996; 29: 386-394. Review.
25. Theodore S, Sharp S, Zhou J, et al. Establishment and characterization of a pair of non-malignant and malignant tumor derived cell lines from an African American prostate cancer patient. Int J Oncol 2010; 37: 1477-1482.
26. Gu Y, Li H, Miki J, et al. Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. Exp Cell Res 2006; 312: 831-843.
27. Weijerman PC, König JJ, Wong ST, et al. Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. Cancer Res 1994; 54: 5579-5583.
28. Rhim JS, Webber MM, Bello D, et al. Immortalization and transformation of adult human prostate epithelial cells by a combination of HPV-18 and v-Ki-ras. Proc Natl Acad Sci U S A 1994; 91: 11874-11878.
29. Bright RK, Vocke CD, Emmert-Buck MR, et al. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res 1997; 57: 995-1002.
30. Iype PT, Iype LE, Verma M, et al. Establishment and characterization of immortalized human cell lines from prostatic carcinoma and benign prostatic hyperplasia. Int J Oncol 1998; 12: 257-263.
31. Choo CK, Ling MT, Chan KW, et al. Immortalization of human prostate epithelial cells by HPV 16 E6/E7 open reading frames. Prostate 1999; 40: 150-158.
32. Yasunaga Y, Nakamura K, Ewing CM, et al. A novel human cell culture model for the study of familial prostate cancer. Cancer Res 2001; 61: 5969-5973.
33. Nakamura K, Yasunaga Y, Ko D, et al. Cadmium-induced neoplastic transformation of human prostate epithelial cells. Int J Oncol 2002; 20: 543-547.
34. Cheung PY, Deng W, Man C, et al. Genetic alterations in a telomerase-immortalized human esophageal epithelial cell line: implications for carcinogenesis. Cancer Lett 2010; 293: 41-51.
35. Caccamo AE, Scaltriti M, Caporali A, et al. Nuclear translocation of a clusterin isoform is associated with induction of anoikis in SV40-immortalized human prostate epithelial cells. Ann N Y Acad Sci 2003; 1010: 514-519.
36. Koochekpour S, Maresh GA, Katner A, et al. Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. Prostate 2004; 60: 141-152.
37. Navone NM, Olive M, Ozen M, et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 1997; 3: 2493-2500.
38. D'Antonio JM, Vander Griend DJ, Antony L, et al. Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling. PLoS One 2010; 5: e11475.
39. Hu S, Delorme N, Liu Z, et al. Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion. Mol Cancer 2010; 9: 30.
40. Makridakis NM, Ross RK, Pike MC, et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999; 354: 975-978.
41. Ntais C, Polycarpou A, Ioannidis JP. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003; 12: 120-126.
42. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225-1229.
43. Paris PL, Kupelian PA, Hall JM, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999; 8: 901-905.
44. Walker AH, Jaffe JM, Gunasegaram S, et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat 1998; 12 (4): 289.
45. deVere White RW, Deitch AD, Jackson AG, et al. Racial differences in clinically localized prostate cancers of black and white men. J Urol 1998; 159: 1979-1982.
46. Jean-Gilles J, Satagopan J, Zhou Q, et al. Different chromosomal alterations correlate with gene expression in African American (AA) versus Caucasian American (CA) prostate cancer (PC) patients. Journal of Clinical Oncology; ASCO Annual Meeting Proceedings Part I. 2007; 25: 5000.
47. Gaston KE, Kim D, Singh S, et al. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 2003; 170: 990-993.
48. Mohler JL, Gaston KE, Moore DT, et al. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol 2004; 171: 2277-2280.
49. Gottlieb B, Beitel LK, Nadarajah A, et al. The androgen receptor gene mutations database: 2012 update. Human Mutation 2012; 33: 887-894.
50. Sun S, Sprenger CC, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120: 2715-2730.